Mixed results for a malaria vaccine

Nature Medicine

Volumn 17, Issue 12, 2011, Pages 1560-1561

  Good, Michael F ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCUMSPOROZOITE PROTEIN, PROTOZOAN; HEPATITIS B SURFACE ANTIGEN; MALARIA VACCINE; PROTOZOAL PROTEIN;

ARTICLE; CHEMISTRY; HUMAN; IMMUNOLOGY; MALARIA; PHASE 3 CLINICAL TRIAL (TOPIC);

CLINICAL TRIALS, PHASE III AS TOPIC; HEPATITIS B SURFACE ANTIGENS; HUMANS; MALARIA; MALARIA VACCINES; PROTOZOAN PROTEINS;

EID: 84856493172     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1211-1560     Document Type: Article

References (10)

1. The RTS, S Cinical Trials Partnership. first results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children.N.Engl.J.Med.published online, doi:10.1056/nejmoa1102287 (18 October 2011).
2. Cohen, J., Nussenzweig, V., Nussenzweig, R., Vekemans, J.& Leach, A.From the circumsporozoite protein to the RTS, S vaccine.Hum.Vaccin.6, 90–96 (2010).
3. Stewart, V. A.et al. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS, S/AS01B improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.Infect.Immun.75, 2283–2290 (2007).
4. Bojang, K. A.et al. Efficacy of RTS, S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: A randomised trial.Lancet 358, 1927–1934 (2001).
5. Good, M. F.Our impasse in developing a malaria vaccine.Cell.Mol.Life Sci.68, 1105–1113 (2011).
6. Barry, A. E., Schultz, L., Buckee, C.O.& Reeder, J.C.et al. Contrasting population structures of the genes encoding ten leading malaria vaccine-candidate antigens of the human malaria parasite, Plasmodium falciparum.PLoS One 4, e8497 (2009).
7. Bejon, P. et al. Efficacy of RTS, S/AS01E vaccine against malaria in children 5 to 17 months of age.N.Engl.J.Med.359, 2521–2532 (2008).
8. Asante, K. P. et al. Safety and efficacy of the RTS, S/AS01(E) candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.Lancet Infect.Dis.11, 741–749 (2011).
9. Moorthy, V., Reed, Z. & Smith, P.G.Measurement of malaria vaccine efficacy in phase III trials: Report of a WHO consultation.Vaccine 25, 5115–5123 (2007).
10. Alonso, P. L. et al. Duration of protection with RTS, S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: Single-blind extended follow-up of a randomised controlled trial.Lancet 366, 2012–2018 (2005).